ARTICLE | Clinical News
Vedolizumab: Phase III started
January 13, 2014 8:00 AM UTC
Takeda began a double-blind, placebo-controlled, Japanese Phase III trial to evaluate 300 mg IV vedolizumab at weeks 0, 2 and 6 and every 8 weeks thereafter as an induction and maintenance therapy in ...